There are currently 702 clinical trials in Orlando, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including AdventHealth Orlando, GSK Investigational Site, Orlando Clinical Research Center and Nemours Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
REBYOTA™ Prospective Registry
NCT05835219
Recruiting
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (prim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Ferring Investigational Site, Orlando, Florida
Conditions: Recurrence of Clostridium Difficile Infection
Register for Updates
A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
NCT06578585
Recruiting
The main goal of this trial is to learn more about the safety and tolerability of Lu AG09222 when taken together with ubrogepant. This includes looking for any new or worsening medical issues the participants have with the treatment. During the trial, participants with migraine will receive ubrogepant oral tablets and an injection of either Lu AG09222 or a placebo.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/13/2025
Locations: Clinical Neuroscience Solutions, Orlando, Florida
Conditions: Migraine
Register for Updates
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT04094610
Recruiting
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). P... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/12/2025
Locations: Arnold Palmer Hospital For Children, Orlando, Florida +1 locations
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
Register for Updates
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
NCT05705531
Recruiting
This study assesses how blood cell growth patterns (clonal hematopoiesis), relates to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If docto... Read More
Gender:
ALL
Ages:
Between 7 years and 40 years
Trial Updated:
02/11/2025
Locations: Arnold Palmer Hospital for Children, Orlando, Florida
Conditions: Hodgkin Lymphoma, Cardiovascular Disorder, Clonal Hematopoiesis
Register for Updates
Healthy Eating and Active Lifestyle (HEAL): Breast Cancer Program Outcomes
NCT06078761
Recruiting
The goal of this single-group prospective study is to examine the impact of the Healthy Eating and Active Lifestyle (HEAL) Breast Cancer program on participants' perceived stress, biometrics, basic labs, lifestyle behaviors, self-efficacy, mental health, and quality of life. Participants will participate in an 8-week program of 90-minute virtual sessions each week to decrease risk of cancer recurrence. Program participants can choose to participate in the research study which will include data... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: AdventHealth, Orlando, Florida
Conditions: Breast Cancer
Register for Updates
Maestro 1.1 Post-Market Registry
NCT06103136
Recruiting
The objective of the study is to observe the real-life usage of the Maestro Platform for surgical assistance in laparoscopic surgery.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/11/2025
Locations: Orlando Veterans Affairs Medical Center, Orlando, Florida
Conditions: Surgery
Register for Updates
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects with Renal Impairment and in Healthy Subjects with Normal Renal Function
NCT06698549
Recruiting
This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with severe renal impairment and subjects without renal impairment, matched for age, body weight and, to the extent possible, for gender. The primary purpose of this study is to characterize the effect of renal impairment on the plasma pharmacokinetics of ALG-097558 following administration of multiple, twice daily (Q12H) oral (PO) doses.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/11/2025
Locations: Orlando Clinical Research Center, Orlando, Florida
Conditions: COVID 19
Register for Updates
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
NCT05512208
Recruiting
The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
02/06/2025
Locations: AdventHealth, Orlando, Florida
Conditions: Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer, Cervical Cancer, Solid Tumor
Register for Updates
Regeneration of Acutely Injured Nerves with Temporary Electrical Stimulation
NCT05721261
Recruiting
A novel temporary peripheral nerve stimulation system that delivers a single dose of electrical stimulation therapy for 1 hour will be evaluated for safety and effectiveness.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/06/2025
Locations: Orlando Health Jewett Orthopedic Institute, Orlando, Florida
Conditions: Nerve Injury
Register for Updates
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT05557045
Recruiting
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Florida Cancer Specialists - Lake Nona, Orlando, Florida
Conditions: Advanced Cancer, Metastatic Cancer, Solid Tumor
Register for Updates
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
NCT04174157
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the c... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/30/2025
Locations: Adventist Health System - Florida, Orlando, Florida
Conditions: Spinal Muscular Atrophy (SMA)
Register for Updates
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects with Hepatic Impairment and in Healthy Subjects with Normal Hepatic Function
NCT06568861
Recruiting
This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with moderate hepatic impairment and subjects without hepatic impairment, matched for age, body weight and, to the extent possible, for gender. The primary purpose of this study is to characterize the effect of hepatic impairment on the plasma pharmacokinetics of ALG-097558 following administration of multiple, twice daily (Q12H) oral (PO) doses.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/29/2025
Locations: Orlando Clinical Research Center, Orlando, Florida
Conditions: COVID-19
Register for Updates